Tag: CD30
ASH 2019: Brentuximab Vedotin + Nivolumab in Frontline and R/R Hodgkin...
Updated and long-term follow-up analyses from two clinical trials evaluating brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda) and nivolumab (Opdivo®; Bristol‑Myers Squibb) in frontline Hodgkin lymphoma...
What to Expect at ASH 2019: Seattle Genetics
With the 61st annual meeting of the American Society of Hematology about to begin, here are some of the presentations to look for.
This year...
The Lancet Publishes Positive Phase III Trial Data of Brentuximab Vedotin...
Data from the randomized Phase III ALCANZA clinical trial evaluating brentuximab vedotin (Adcetris®) in patients with cutaneous T-cell lymphoma (CTCL) were published in the...
Anna Sureda MD PhD: “An Intelligent Way to Deliver High Doses...
Surrounded by fantastical and modernist landmarks designed by Antoni Gaudí, Barcelona, in the northeast of Spain, is a surreal wonderland where mansions look like...
Breakthrough Therapy Designation for Brentuximab Vedotin in CD30-expressing Mycosis Fungoides and...
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for brentuximab vedotin (Adcetris®; Seattle Genetics) for the treatment of patients with...
Phase II Trial Evaluates Brentuximab Vedotin in Systemic Lupus Erythematosus
A new phase II clinical trial designed to evaluate the safety and efficacy of brentuximab vedotin (Adcetris®; Seattle Genetics) in systemic lupus erythematosus also known...
Brentuximab Vedotin Data from the AETHERA Post-Transplant Consolidation Setting Presented at...
Data from brentuximab vedotin (Adcetris®; Seattle Genetics) in the AETHERA post-transplant consolidation setting for Hodgkin lymphoma (HL) and in frontline diffuse large B-cell lymphoma...
Supplemental BLA for Brentuximab Vedotin in Post-Transplant Hodgkin Lymphoma Patients at...
Based on positive data from the Phase III AETHERA trial (SGN35-005; NCT01100502) of brentuximab vedotin (Adcetris®; Seattle Genetics, Inc/Takeda Oncology) as consolidation therapy immediately following...
Brentuximab Vedotin Shows 42% Objective Response Rate in Patients with Relapsed...
New, updated, data from a phase II clinical trial of brentuximab vedotin (Adcetris®; Seattle Genetics) in patients with diffuse large B-cell lymphoma or DLBCL and other B-cell non-Hodgkin lymphomas, demonstrated an encouraging activity and tolerability profile in the relapsed and refractory setting. The results were presented at the 55th annual meeting of ASH®, the American Society of Hematology, held in New Orleans, Louisiana, USA, from December 7 - 10, 2013.
Phase III Front-line Trial Planned with Brentuximab Vedotin in Advanced Stage...
Interim results from a phase I clinical trial of brentuximab vedotin(SGN-35, Adcetris™, Seattle Genetics/Millennium: The Takeda Oncology Company) in combination with chemotherapy for the...